9605 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Reports First Quarter 2026 Operational Highlights and Financial Results
Analysis of Tumor and Biomarker Responses in the VIRAGE Trial, a Randomized Phase IIb, Open-Label, Study of Nab-Paclitaxel and Gemcitabine with/without Intravenous VCN-01 in Patients with Metastatic Pancreatic Cancer (mPDAC)
Other Events
Reg. FD, Other Events
Reports Full-Year 2025 Operational Highlights and Financial Results
Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
Unique Oncolytic Virus Therapies for Multiple Solid Tumors January 2026
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
PRE 14A
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Correspondence